SCHEMBL5539637

SCHEMBL5539637

Cc1nc(-c2cccc(F)c2)oc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.50
SLC9A1 P19634 1/20 0.50
NOTUM Q6P988 2/20 0.47
TP53 P04637 1/20 0.45
HPN P05981 1/20 0.45
UTRN P46939 2/20 0.44
GUSB P08236 1/20 0.44
KDM4E B2RXH2 2/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
GRM5 P41594 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539633 0.83 MAOB (0.48) MAOBSLC9A1NOTUMTP53HPN
SCHEMBL5543447 0.83 SLC9A1 (0.48) MAOBSLC9A1NOTUMTP53HPN
SCHEMBL12163868 0.80 KDM4E (0.50) MAOBSLC9A1HPNKDM4EALDH1A1
SCHEMBL4830084 0.80 KDM4E (0.50) MAOBSLC9A1NOTUMHPNKDM4E
SCHEMBL5536101 0.79 NPC1 (0.53) MAOBSLC9A1NOTUMTP53NPC1
SCHEMBL3590075 0.79 HDAC6 (0.47) MAOBGUSBMGAMGAASI
SCHEMBL5543997 0.78 NPC1 (0.52) NOTUMTP53KDM4EGAANPC1
SCHEMBL436384 0.77 GAA (0.57) KDM4EGAANPC1ALDH1A1HPGD
SCHEMBL6509332 0.77 PPARG (0.52) SLC9A1KDM4EALDH1A1KMT2A
SCHEMBL4418435 0.74 BRD4 (0.57) NOTUMUTRNKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885SLC9A1 2413/4885NOTUM 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.